06/18/2026
We are thrilled 💥to announce positive results with our novel small molecule DB-006 in preclinical studies of atopic dermatitis (AD). AD, commonly known as eczema, is a chronic inflammatory skin condition affecting up to 30% of children and 10% of adults worldwide. It is characterized by dry, scaly, intensely itchy rashes. AD carries one of the highest global disability burdens and significantly impairs a disease sufferers quality of life. A sizeable proportion of AD sufferers still lack adequate disease control with current topical therapies.
VANCOUVER, British Columbia, June 18, 2026 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc., a Vancouver-based biopharmaceutical company focused on...